Communiqués Emergent BioSolutions Inc.

Actions

EBS

US29089Q1058

Produits pharmaceutiques

Marché Fermé - NYSE 22:00:02 02/09/2026			Varia. 5j.	Varia. 1 janv.
6,460 ^USD	+3,86%		+8,21%	-47,73%

01/09	Emergent BioSolutions Inc. reçoit une modification de contrat d'environ 24 millions USD de la part de la Biomedical Advanced Research and Development Authority pour la fourniture de CYFENDUS (vaccin contre le charbon adsorbé, avec adjuvant)	CI
01/09	Emergent BioSolutions décroche un contrat de 24 millions de dollars auprès de la BARDA pour un vaccin contre la maladie du charbon	MT

Communiqués

01/09	Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)	GL
31/08	Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray	GL
31/08	Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day	GL
05/08	Emergent Biosolutions: Q2 Earnings Snapshot	AQ
05/08	Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment	GL
05/08	Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment	AQ
05/08	Emergent BioSolutions Reports Second Quarter 2026 Financial Results	GL
22/07	Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026	GL
29/06	Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government	GL
05/06	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose	AQ
04/06	Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose	AQ
28/05	Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy	GL
20/05	Emergent BioSolutions to Participate in Upcoming Investor Conferences	GL
18/05	Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]	GL
30/04	Emergent Biosolutions: Q1 Earnings Snapshot	AQ
30/04	Emergent BioSolutions Reports First Quarter 2026 Financial Results	GL
30/04	Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox	GL
29/04	Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142	GL
29/04	Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives	GL
29/04	Davis Schneider's brother died of an overdose. The Blue Jay says naloxone can save others	AQ
28/04	Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States	GL
28/04	Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States	AQ
16/04	Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026	GL
16/04	Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility	GL
16/04	Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility	AQ